Home Cart Sign in  
Chemical Structure| 1386874-06-1 Chemical Structure| 1386874-06-1

Structure of Samotolisib
CAS No.: 1386874-06-1

Chemical Structure| 1386874-06-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK with an IC50 of 64.9 nM, 42.1 nM, 10.6 nM, 19.1 nM for Akt1 (pT308), Akt1 (pS473), P70S6 (pT389), S6RP (pS240/242).

Synonyms: LY3023414; GTPL8918

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Samotolisib

CAS No. :1386874-06-1
Formula : C23H26N4O3
M.W : 406.48
SMILES Code : O=C(N1C[C@@H](OC)C)N(C)C2=C1C3=CC(C4=CC(C(C)(O)C)=CN=C4)=CC=C3N=C2
Synonyms :
LY3023414; GTPL8918
MDL No. :MFCD28411368
InChI Key :ACCFLVVUVBJNGT-AWEZNQCLSA-N
Pubchem ID :57519748

Safety of Samotolisib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Samotolisib

DNA
PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • PI3K

  • mTOR

  • DNA-PK

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293 cells 79.67 ± 7.17 nM (IC50) 72 h To evaluate the cytotoxic effect of LY3023414 on cells overexpressing ABCB1 or ABCG2, results showed that HEK293 cells were sensitive to LY3023414 PMC7606332
Human lung cancer H460 cells 20.87 ± 0.68 nM (IC50) 72 h To evaluate the cytotoxic effect of LY3023414 on cells overexpressing ABCB1 or ABCG2, results showed that H460 cells were sensitive to LY3023414 PMC7606332
Human colon cancer S1 cells 84.39 ± 15.65 nM (IC50) 72 h To evaluate the cytotoxic effect of LY3023414 on cells overexpressing ABCB1 or ABCG2, results showed that S1 cells were sensitive to LY3023414 PMC7606332
Human epidermal cancer KB-3-1 cells 67.20 ± 6.52 nM (IC50) 72 h To evaluate the cytotoxic effect of LY3023414 on cells overexpressing ABCB1 or ABCG2, results showed that KB-3-1 cells were sensitive to LY3023414 PMC7606332
Human ovarian cancer OVCAR-8 cells 44.54 ± 2.20 nM (IC50) 72 h To evaluate the cytotoxic effect of LY3023414 on cells overexpressing ABCB1 or ABCG2, results showed that OVCAR-8 cells were sensitive to LY3023414 PMC7606332
Murine bone marrow-derived macrophage cells (BMMs) 2.5, 5, 10, 20, 40, 80, 160 nM LY3023414 inhibited osteoclastogenesis through the PI3K/Akt/GSK3β/nuclear factor- activated T cell 1 (NFATc1) pathway, but has little impact on the function of mature osteoclasts. PMC8076989
Murine preosteoblast MC3T3-E1 cells 10, 20, 40, 80, 160 nM 7 or 21 days LY3023414 suppressed osteogenesis both in the early stage of differentiation and late stage of calcification through the PI3K/Akt/GSK3β/β-catenin signalling pathway. PMC8076989
DFCI316KRASQ61H 100nM 72 h Inhibition of PI3K/mTOR signaling pathway, combined with LY3214996 showed enhanced anti-proliferative activity PMC8026682
DFCI24KRASG12C 100nM 72 h Inhibition of PI3K/mTOR signaling pathway, combined with LY3214996 showed enhanced anti-proliferative activity PMC8026682
AP mouse colon cancer cells 200, 400, 600 nM 48 h LY3023414 significantly reduced the growth of AP mouse colon cancer spheroids, decreased cellular proliferation and increased differentiation PMC5550373

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice 22RV1 and PC3 xenograft models Intravenous 15 mg/kg Every 4 days for 28 days Evaluate the anti-tumor efficacy of LY3023414 in 22RV1 and PC3 xenograft models. Results showed that LY3023414 significantly inhibited tumor growth at 15 mg/kg dose, with tumor growth inhibition rates of 72% and 78% in 22RV1 and PC3 models, respectively. PMC11705819
NSG mice DFCI24KRASG12C tumor model Oral 15mg/kg Twice daily, for 4 weeks Combined with LY3214996 showed significant tumor growth inhibition and partial tumor regression PMC8026682
Mice AP mouse colon cancer model Oral 20 mg/kg Once daily for 14 days LY3023414 demonstrated significant anti-tumor activity in the AP mouse colon cancer model, reducing tumor volume and SUV PMC5550373

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02549989 Endometrial Cancer|Recurrent E... More >>ndometrial Cancer Less << PHASE2 COMPLETED 2022-03-23 Memorial Sloan Kettering at Ba... More >>sking Ridge, Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Commack, Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester, Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, 11553, United States Less <<
NCT02536586 Neoplasm PHASE1 COMPLETED 2017-02-09 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Chiba, 277 8577, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Tokyo, 104-0045,, Japan Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.46mL

0.49mL

0.25mL

12.30mL

2.46mL

1.23mL

24.60mL

4.92mL

2.46mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories